2003 Disease Vaccine Virus 
Drug Discovery World
MAY 15, 2024
Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.
PLOS: DNA Science
JULY 27, 2023
That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 18, 2021
Northwestern Medicine scientists have shown for the first time that coronavirus vaccines and prior coronavirus infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines that could prove useful in the face of future epidemics.
NIH Director's Blog: Drug Development
MAY 21, 2020
B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. Monoclonal antibodies are currently used to treat a variety of conditions, including asthma, cancer, Crohn’s disease, and rheumatoid arthritis.
NIH Director's Blog: Drug Development
MARCH 18, 2021
He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. These days, the Veesler lab has been hard at work to understand SARS-CoV-2 and the human immune response to the virus. Despite carrying all of these viruses, bats rarely show symptoms of being sick.
The Pharma Data
DECEMBER 23, 2020
AIM announced in October that the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) clinical trial received IRB approval to include patients previously diagnosed with SARS-CoV-2 – which causes the disease COVID-19 – but who now demonstrate post-acute infection chronic fatigue-like symptoms. See: PLOS ONE ). AIM CEO Thomas K.
The Pharma Data
APRIL 25, 2021
Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. 1 – 5. RSV is the most common cause of LRTI and the leading cause of hospitalizations in all infants.
Expert insights. Personalized for you.
130 
Let's personalize your content